ASX Top 200 Stocks Down Under 9 May 2022: Healius (ASX:HLS)

Healius: It's not just a one-trick pony
Pathology is one of the most important branches of medicine, accounting for 70% of all healthcare decisions. Amidst the pandemic it has boomed because of COVID-19 testing but even that came at the expense of other services. Healius is not the only pathology stock on the ASX but we are most bullish on it because it's 'landing' back to normality will be softer than its peers because it offered a broader range of services including day surgery and radiology.   Click here to read the previous edition of ASX Top 200 Stocks Down Under published 2 May 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks